Background
==========

The human gene *SEPS1*, located on chromosome 15q26.3, encodes selenoprotein S which participates in the retro-translocation of misfolded proteins from the endoplasmic reticulum (ER) to the cytosol for their degradation \[[@B1]\]. This ER membrane protein functions in stress responses to prevent the deleterious consequences of accumulation of misfolded proteins, accumulation that has been linked to immune and inflammatory processes \[[@B2]\]. A study identified the strong association of the proximal promoter *SEPS1*polymorphism at -105G/A with circulating levels of three pro-inflammatory cytokines, interleukin (IL)-6, IL-1β and TNF-α \[[@B3]\]. Moreover, these authors reported that the mutant variant significantly reduced the promoter activity of the *SEPS1*gene in stressed HepG2 cells and that the suppression of this gene by short interfering RNA increased the release of pro-inflammatory cytokines in a macrophage cell line. A regulatory loop has been recently proposed whereby cytokines stimulate the expression of *SEPS1*, which in turn diminishes cytokine production \[[@B4]\].

The murine homolog gene of the human *SEPS1*is the *Tanis*gene, which encodes a serum amyloid A receptor \[[@B5]\]. Acute phase serum amyloid A proteins (SAAs) are multifunctional apolipoproteins produced in large amounts during the acute phase of inflammation and also during the development of chronic inflammatory diseases. SAAs are involved in the pathogenesis of several chronic inflammatory diseases, such as rheumatoid arthritis (RA) \[[@B6]-[@B9]\], multiple sclerosis (MS)\[[@B10]\] and inflammatory bowel diseases (IBD) \[[@B11]-[@B13]\]. It is believed that locally synthesized SAA by synovial cells in the inflamed joints acts as an autocrine inducer of matrix metalloproteinase-1 and causes extensive joint erosion \[[@B14]\].

Altogether these data point to the important role of selenoprotein S mediating inflammation, and we aimed at testing whether the *SEPS1*gene was involved in the development of inflammatory autoimmune complex diseases. These are multifactorial traits influenced by both genetic predisposing factors and environmental triggers. The activation of *SEPS1*expression by fasting *in vivo*and by glucose-deprivation *in vitro*allowed its assignation to the glucose-regulated protein family \[[@B5],[@B15]\]. Furthermore, a locus on 15q26, IDDM3, was described to increase susceptibility to type 1 diabetes, T1D \[[@B16],[@B17]\]. Therefore, we decide to test the *SEPS1*polymorphisms for association with diabetes risk in a cohort of Spanish T1D patients. Additionally, we pursued to study two other autoimmune diseases with an important inflammatory component, rheumatoid arthritis and the inflammatory bowel diseases, Crohn\'s disease (CD) and ulcerative colitis (UC). Provided this candidate gene previously related with the inflammatory response shows any influence on the pathogenesis of these diseases, a new mechanistic tool for treatment would be available.

Methods
=======

Patients and controls
---------------------

The study group consisted of 592 RA, 674 IBD and 311 T1D unrelated patients, consecutively recruited from one centre, either Hospital Clínico San Carlos or Hospital Ramón y Cajal (Madrid, Spain).

T1D patients (median age at onset 15 years) diagnosed according to the criteria of the American Diabetes Association (ADA), were insulin-dependent at the time to study.

RA diagnosis was established based on the American College of Rheumatology (ACR) criteria \[[@B18]\] and samples were previously genotyped for HLA-DRB1. Mean age at onset was 54 ± 14 years; 61% of the patients carried the shared epitope; 66% and 50% of the patients were positive for rheumatoid factor and for anti-cyclic citrullinated peptide, respectively, and 32% of the patients presented nodular disease.

Diagnosis of IBD patients was based on standard clinical, radiologic, endoscopic and histologic criteria \[[@B19]\]. The mean age at onset for UC patients was 38 years; 41% of the patients presented pancolitis; 47% and 13% of the patients suffered extraintestinal manifestations and colectomy, respectively. CD patients were classified according to the location of the lesions in ileal (L1, 48%), colonic (L2, 16%), ileocolonic (L3, 32%) and upper gastrointestinal tract (L4, 3%) and according to the disease behavior in inflammatory (B1, 43%), stricturing (B2, 15%) and perforating (B3, 42%). Only 20% of the CD patients debuted after the age of 40.

A group of 550 healthy unrelated subjects from Madrid (mainly hospital employees and blood donors) were selected as controls. Cases and controls were all white Spanish subjects and were included in this study after written informed consent. The Ethics Committee of Hospital Clínico (Madrid) approved the study.

*SEPS1*polymorphisms
--------------------

The *SEPS1*polymorphisms (rs11327127, rs28665122, rs4965814, rs12917258, rs4965373 and rs2101171) were genotyped using TaqMan assays from Applied Biosystems following manufacturer\'s suggestions and analyzed in an ABI 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Their location is indicated by the distance from the transcription start site: two of them are in the promoter region; another two in intron 5; rs4965373 depending of alternative splicing is either in intron 6 or in the 3\'UTR region; and the last one is downstream at 9707 (see Table [1](#T1){ref-type="table"}).

###### 

Genotypic frequencies of the *SEL-S*polymorphisms in Spanish T1D, RA and IBD patients and controls.

                               **T1D patients**   **RA patients**   **CD patients**   **UC patients**   **Controls**
  ---------------------------- ------------------ ----------------- ----------------- ----------------- --------------
  ***-538 SEPS1*rs11327127**                                                                            
  TT                           183 (59%)          212 (59%)         218(62%)          235 (62%)         306 (60%)
  T delT                       106 (34%)          127 (35%)         111 (32%)         124 (32%)         180 (35%)
  delT delT                    21 (7%)            20 (6%)           21 (6%)           22 (6%)           28 (5%)
  ***-105 SEPS1*rs28665122**                                                                            
  CC                           216 (70%)          253 (70%)         253(73%)          274 (71%)         360 (72%)
  CT                           85 (27%)           92 (26%)          83 (24%)          100 (26%)         124 (25%)
  TT                           9 (3%)             14 (4%)           12 (3%)           11 (3%)           14 (3%)
  ***SEPS1 3705*rs4965814**                                                                             
  TT                           195 (63%)          224 (62%)         215 (68%)         225 (64%)         334 (65%)
  TC                           103 (33%)          118 (33%)         82 (26%)          112 (32%)         161 (31%)
  CC                           12 (4%)            17 (5%)           19 (6%)           12 (4%)           20 (4%)
  ***SEPS1 4283*rs12917258**                                                                            
  CC                           148 (48%)          150 (42%)         164 (46%)         165 (44%)         215 (42%)
  CG                           137 (44%)          163 (45%)         149 (42%)         173 (46%)         247 (48%)
  GG                           25 (8%)            46 (13%)          40 (11%)          38 (10%)          49 (10%)
  ***SEPS1 5227*rs4965373**                                                                             
  GG                           145 (47%)          187 (52%)         182 (52%)         178 (48%)         246 (48%)
  GA                           127 (41%)          142 (40%)         136 (39%)         163 (43%)         220 (43%)
  AA                           38 (12%)           30 (8%)           33 (9%)           33 (9%)           43 (9%)
  ***SEPS1 9707*rs2101171**                                                                             
  TT                           177 (57%)          218 (61%)         216 (61%)         223 (59%)         296 (58%)
  TC                           113 (37%)          130 (36%)         122 (34%)         138 (37%)         191 (37%)
  CC                           20 (6%)            11 (3%)           16 (5%)           17 (4%)           26 (5%)

Statistical Analysis
--------------------

Allele and genotype frequencies in patients and controls were compared by χ^2^test or Fisher exact test when necessary; p values were considered significant at a level of \<0.05. Odds ratio (OR) and p values were calculated using a standard package (Epi Info v. 6.02, CDC, Atlanta, USA). For an OR = 1.5, the statistical power of our cohorts ranged from 80 -- 95% depending on the specific polymorphism analyzed.

Haplotypic frequencies were estimated using the Expectation-Maximization algorithm implemented in the Arlequin v2.000 software \[[@B20]\] with number of iterations set at 5000 and initial conditions at 50, with an epsilon value of 10^-7^.

Results and discussion
======================

The present study investigates the influence of all *SEPS1*variants previously correlated with increased pro-inflammatory cytokines levels (polymorphisms at -105G/A, 3705G/A and 5227C/T) and of the *SEPS1*haplotypes on predisposition to inflammatory complex diseases.

We first analyzed the functional *SEPS1*promoter polymorphism at -105G/A and no significant differences in genotypic frequencies were observed when healthy controls were compared with patients suffering from T1D, RA or IBD (Table [1](#T1){ref-type="table"}). As two other variants (rs4965814 and rs4965373) have been associated with high plasma cytokine levels \[[@B3]\], we studied them in our cohorts, and the distribution of genotypes followed the same pattern in patients and in controls (Table [1](#T1){ref-type="table"}).

We selected three additional polymorphisms along the gene from those described by Curran et al \[[@B3]\] in order to analyze the haplotypes inferred by applying the Expectation-Maximization algorithm implemented in the Arlequin software. No significant difference in haplotype frequencies was observed after appropriate correction for multiple testing in any diseased cohort (Table [2](#T2){ref-type="table"}).

###### 

Haplotypes estimated within the *SEPS1*gene (alleles at -538/-105/3705/4283/5227/9707) and their distribution in patients and healthy individuals.

                   **T1D (2n = 620)**   **RA (2n = 718)**   **CD (2n = 582)**   **UC (2n = 664)**   **Controls (2n = 982)**                                     
  ---------------- -------------------- ------------------- ------------------- ------------------- ------------------------- ----- ---------- ----- ---------- -----
  **TCTGGT**       0.28827              179                 0.32557             234                 0.334699                  195   0.339168   225   0.325571   320
  **TCTCGT**       0.1716               106                 0.1711              123                 0.185524                  108   0.176243   117   0.171104   168
  **TCTCAC**       0.16575              103                 0.15691             113                 0.140554                  82    0.161364   107   0.156905   154
  **DelT TCCGT**   0.13375              83                  0.12057             87                  0.124047                  72    0.122667   81    0.120574   118
  **DelT CTCAC**   0.06887              43                  0.07503             54                  0.063144                  37    0.051819   34    0.075028   74
  **TCTCAT**       0.07046              44                  0.05216             37                  0.069939                  41    0.060517   40    0.052158   51
  **TCCCGT**       0.02949              18                  0.02635             20                  0.027632                  16    0.027826   18    0.026349   26
  **TTCCGT**       0.01231              8                   0.01671             12                  0.011366                  7     0.010658   7     0.018029   18
  **DelT CCCGT**   0.00875              5                   0.01114             8                   0.019499                  11    0.015959   11    0.015536   15
  **Others**       0.05075              31                  0.04178             30                  0.023596                  13    0.033779   24    0.038746   38

A direct functionality has been attributed to the *SEPS1*promoter polymorphism at -105G/A, increasing plasma levels of the aforementioned cytokines presumably due to the disruption of an ER stress element (ERSE). Two other tested variants have also been strongly related with the circulating levels of the inflammatory cytokines \[[@B3]\]. In contrast, a recent report did not find consistent association of this polymorphism with circulating levels of either IL-6 or TNF-α \[[@B21]\]. We did not observe differences in the genotypic distribution of the *SEPS1*polymorphisms analyzed in Spanish cohorts between patients suffering from autoimmune diseases with a clear inflammatory component, like T1D, RA or IBD, and controls. The analysis of *SEPS1*haplotypic frequencies did not differ between patients and healthy individuals either.

Given that evidences exist for the affected expression and activity of some selenoproteins depending on sexual dimorphism in mouse \[[@B22]\] and human \[[@B23]\], we decided to check for a gender specific association of -105G/A *SEPS1*polymorphism with the autoimmune disorders under study; however, we did not detect a gender-bias in our results. No significant difference between sex-stratified cohorts was found for any of the polymorphisms studied (Table [3](#T3){ref-type="table"}).

###### 

Genotype frequencies of *SEPS1*polymorphisms in Spanish patients stratified by gender.

                               **T1D Women (n, %)**   **T1D Men (n, %)**   **RA Women (n, %)**   **RA Men (n, %)**   **CD Women (n, %)**   **CD Men (n, %)**   **UC Women (n, %)**   **UC Men (n, %)**
  ---------------------------- ---------------------- -------------------- --------------------- ------------------- --------------------- ------------------- --------------------- -------------------
  ***-538 SEPS1*rs11327127**                                                                                                                                                         
  TT                           90 (58)                93 (60)              160 (59)              49 (60)             108 (60)              109 (64)            97 (64)               135 (60)
  T delT                       53 (34)                53 (34)              100 (37)              24 (30)             61 (34)               50 (30)             49 (33)               72 (32)
  delT delT                    12 (8)                 9 (6)                12 (4)                8 (10)              10 (6)                10 (6)              4 (3)                 18 (8)
  ***-105 SEPS1*rs28665122**                                                                                                                                                         
  CC                           107 (69)               109 (70)             191 (70)              58 (71)             128 (72)              123 (73)            106 (71)              160 (71)
  CT                           43 (28)                42 (27)              70 (26)               20 (25)             44 (25)               38 (23)             42 (28)               56 (25)
  TT                           5 (3)                  4 (3)                11 (4)                3 (4)               5 (3)                 7 (4)               2 (1)                 9 (4)
  ***SEPS1 3705*rs4965814**                                                                                                                                                          
  TT                           99 (64)                96 (62)              172 (63)              49 (60)             109 (68)              104 (68)            92 (69)               129 (62)
  TC                           50 (32)                53 (34)              87 (32)               28 (35)             43 (27)               40 (26)             38 (29)               70 (34)
  CC                           6 (4)                  6 (4)                13 (5)                4 (5)               8 (5)                 10 (6)              3 (2)                 9 (4)
  ***SEPS1 4283*rs12917258**                                                                                                                                                         
  CC                           82 (53)                66 (43)              109 (40)              39 (48)             78 (43)               84 (50)             69 (47)               92 (41)
  CG                           61 (39)                76 (49)              124 (46)              35 (43)             85 (47)               63 (37)             59 (40)               113 (51)
  GG                           12 (8)                 13 (8)               39 (14)               7 (9)               17 (9)                23 (13)             20 (13)               18 (8)
  ***SEPS1 5227*rs4965373**                                                                                                                                                          
  GG                           71 (46)                74 (48)              150 (55)              34 (42)             92 (51)               89 (53)             74 (51)               102 (46)
  GA                           61 (39)                66 (42)              103 (38)              37 (45)             72 (40)               62 (37)             51 (35)               105 (48)
  AA                           23 (15)                15 (10)              19 (7)                10 (12)             16 (9)                17 (10)             20 (14)               13 (6)
  ***SEPS1 9707*rs2101171**                                                                                                                                                          
  TT                           87 (56)                90 (58)              172 (63)              43 (53)             111 (61)              105 (61)            96 (64)               124 (55)
  TC                           55 (36)                58 (37)              91 (34)               36 (44)             64 (35)               56 (33)             40 (27)               95 (43)
  CC                           13 (8)                 7 (5)                9 (3)                 2 (3)               6 (3)                 10 (6)              13 (9)                4 (2)

*SEPS1*expression was not significantly altered in intestinal epithelial cells of IBD murine models or in intestinal biopsies from IBD patients when compared with that present in controls \[[@B24]\]. Concordantly, a study testing the association of the promoter variant at -105 with cerebrovascular disease found no influence on stroke risk \[[@B25]\]. Both studies are in agreement with our results that showed lack of association between *SEPS1*polymorphisms and susceptibility to chronic inflammatory diseases. Moreover, a Finnish study of five variants in the *SEPS1*gene locus showed no significant difference between carriers/non-carriers when cardiovascular cases and healthy individuals were compared. The authors suggested that two polymorphisms contribute to the risk for coronary heart disease and for ischemic stroke in females; interestingly, the associated polymorphisms do not correspond with the one at -105G/A \[[@B21]\]. Therefore, evidences are mounting against the role of the *SEPS1*gene in all these conditions, with the only exception to this point of one report defining the minor allele at -105G/A *SEPS1*as a risk factor for preeclampsia in a large Norwegian cohort \[[@B26]\].

Conclusion
==========

The Wellcome Trust Case Control Consortium published recently a genome wide association study for several inflammatory conditions, such as RA, T1D or CD \[[@B27]\] Although the chromosomal region where the gene maps did not show association for any of the mentioned diseases, the *SEPS1*polymorphisms were not analyzed and therefore their involvement in susceptibility could not be formally excluded. Ours is a thorough study analyzing the influence of six polymorphisms along the *SEPS1*gene on susceptibility to common diseases, unravelling lack of association. Our data allow discardind a major individual role of this gene in the aetiology of the studied polygenic diseases.
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